Aspirin Price Index 2025: Tracking Global Shifts in Pharmaceutical Raw Material Costs

Aspirin, also known as acetylsalicylic acid, is a widely used pharmaceutical compound offering relief from pain, reduction in inflammation, and fever management across global healthcare markets. Produced through the esterification of salicylic acid with acetyl chloride, aspirin serves critical functions in treating mild to moderate pain, managing inflammatory conditions like arthritis, and preventing cardiovascular events through its anti-platelet properties.

Global Market Overview:

Globally, the aspirin market reached USD 2.49 Billion in 2024. Projections from IMARC Group suggest the market will grow to USD 3.45 Billion by 2033, representing a compound annual growth rate (CAGR) of 3.52% during 2025-2033. IMARC Group growth is being driven by the medication's expanding role in preventative healthcare, particularly for cardiovascular disease and stroke prevention in aging populations.

Aspirin Price Trend Q2 2025:

To access real-time prices Request Sample

What moved prices:

• USA: A substantial price decline in April was triggered by massive inventory buildup from preemptive purchasing ahead of anticipated Chinese import tariffs. When tariff implementation was delayed, the resulting oversupply situation suppressed immediate demand as market participants absorbed the initial shock without fully passing costs to consumers.
• China: Prices experienced notable declines driven by weak international demand coinciding with a sharp contraction in China's manufacturing Purchasing Managers' Index, signaling slowing industrial activity.
• Germany: April witnessed significant price drops attributed primarily to oversupply from diverted US-bound cargo creating surplus stock in European ports. Pre-holiday stockpiling by distributors and buyers ahead of seasonal breaks amplified the glut, compelling sellers to adjust pricing downward to move excess inventory.
• India: Despite positive short-term price movements reaching USD 2,965/MT in June, Indian manufacturers maintained cautious production discipline, avoiding overproduction commitments due to uncertainties in global trade policies and volatile freight conditions.
• Italy: The Italian market absorbed ripple effects from European supply glut conditions as reduced shipping capacity at critical hubs including Hamburg and Rotterdam delayed deliveries. Port congestion created temporary oversupply situations while simultaneously increasing landed costs for Italian importers working to secure timely shipments.

Drivers Influencing the Market:

1. Trade Policies, Tariffs, and Geopolitical Tensions: International trade restrictions, particularly US tariffs on Chinese pharmaceutical imports, fundamentally reshaped global aspirin trade flows during Q2 2025. Tariff implementation uncertainties drove aggressive preemptive purchasing and stockpiling behaviors.
2. Inventory Management and Strategic Stockpiling: Anticipatory inventory buildup ahead of expected tariff increases created unprecedented stock levels across multiple regions, fundamentally distorting normal supply-demand equilibriums.
3. Healthcare Sector Demand and Demographic Trends: Underlying long-term growth in aspirin consumption stems from aging global populations requiring cardiovascular disease management and stroke prevention therapies.
4. Logistics, Shipping Costs, and Port Infrastructure: Global pharmaceutical supply chains faced significant disruptions from port congestion at major European and Asian hubs, creating delays and increasing landed costs.
5. Currency Exchange Rate Fluctuations: Currency movements significantly impacted regional pricing competitiveness and import costs throughout Q2 2025. A weaker Chinese yuan made Chinese exports more price-competitive in global markets, though this advantage was partially offset by US tariff impositions.
6. Manufacturing Economics and Feedstock Costs: Aspirin production economics depend on salicylic acid feedstock availability and pricing, energy costs for chemical synthesis, and manufacturing capacity utilization rates.

Recent Highlights & Strategic Developments:

• In November 2024, Andhra Sugars Ltd received US FDA approval for its aspirin facility in Venkatarayapuran, India, following rigorous inspection, enabling entry into the U.S. market and diversifying global aspirin supply beyond China and Europe.
• In July 2024, RMIT University researchers reported that low-dose aspirin effectively treated flu-related blood vessel inflammation, improving placental blood flow in pregnancy, potentially expanding aspirin’s medical use into maternal healthcare and pregnancy management applications.
• In February 2023, Bayer AG formed a strategic partnership with Huma Therapeutics to develop the “Bayer Aspirin Heart Risk Assessment,” a digital tool designed to assess cardiovascular risk, enhance preventive healthcare, and support patient education.

Outlook & Strategic Takeaways:

Looking ahead, the global aspirin market is driven by aging demographics in developed markets requiring cardiovascular disease management, expanding healthcare access in emerging economies, and ongoing medical research validating additional therapeutic applications.

To navigate this complex landscape, stakeholders should:

• Monitor aspirin prices across major regional markets monthly to identify inflection points signaling inventory normalization completion, demand recovery, or new trade policy impacts. Track price differentials between US, Chinese, European, and Indian suppliers to optimize procurement strategies based on total landed cost considerations including tariffs and freight.
• Diversify supply sources strategically across multiple geographic origins to mitigate trade policy risks, tariff exposure, and single-region supply disruptions. The substantial price spread between Chinese producers (USD 2,563/MT) and US manufacturers (USD 3,023/MT) reflects not only tariff impacts but also quality specifications, regulatory compliance standards, and supply security premiums that procurement teams must evaluate holistically.
• Assess inventory positioning carefully against demand forecasts to avoid the destocking pressures that characterized Q2 2025. Maintain disciplined just-in-time inventory management rather than aggressive stockpiling unless trade policy changes create clear economic incentives. Monitor competitor inventory levels and industry stockpile data to anticipate market oversupply or tightness conditions.
• Track upstream feedstock costs, particularly salicylic acid pricing, and manufacturing input expenses including energy costs that significantly impact European producer competitiveness. Monitor manufacturing capacity utilization rates across regions to anticipate supply tightness or abundance conditions that influence negotiating leverage with suppliers.
• Evaluate logistics and shipping route alternatives to mitigate port congestion impacts at traditional European and Asian hubs. Consider alternative routing options, direct shipping arrangements, and regional distribution strategies that reduce exposure to bottleneck infrastructure points. Factor rising freight costs and vessel availability constraints into procurement planning and pricing negotiations.
• Monitor regulatory and trade policy developments continuously, particularly US pharmaceutical import regulations, China-US trade negotiations, and tariff structure changes affecting active pharmaceutical ingredient sourcing. Engage in scenario planning for various policy outcomes to ensure procurement strategy flexibility and rapid response capabilities.
• Leverage emerging therapeutic research on aspirin's expanded medical applications, particularly cardiovascular prevention protocols and new indication discoveries, to anticipate demand shifts across healthcare segments. Understanding evolving medical usage patterns provides leading indicators for consumption trend changes.
• Assess quality specifications and regulatory compliance requirements when evaluating alternative suppliers, recognizing that FDA-approved facilities command pricing premiums reflecting certification costs and quality assurance investments. Balance cost optimization against supply chain risk management and regulatory compliance assurance.

Subscription Plans & Customization:

IMARC offers flexible subscription models to suit varying needs:

• Monthly Updates — 12 deliverables/year
• Quarterly Updates — 4 deliverables/year
• Biannual Updates — 2 deliverables/year

Each includes detailed datasets (Excel + PDF) and post-report analyst support.